Warach Steven, Latour Lawrence L
National Institute of Neurological Disorders & Stroke, 10 Center Drive, MSC 1063, Building 10, Room B1D733, Bethesda, MD 20892-1063, USA.
Stroke. 2004 Nov;35(11 Suppl 1):2659-61. doi: 10.1161/01.STR.0000144051.32131.09. Epub 2004 Oct 7.
Loss of integrity of the blood-brain barrier (BBB) resulting from ischemia and reperfusion is a hypothesized precursor to hemorrhagic transformation (HT) and worse clinical outcome than would be expected from the beneficial effects of reperfusion. We used a novel magnetic resonance imaging marker to characterize early BBB disruption in acute focal brain ischemia and tested associations with reperfusion, HT, and poor outcome (modified Rankin score >2). The BBB disruption was evident as delayed gadolinium enhancement of cerebrospinal fluid space on fluid-attenuated inversion recovery (FLAIR) images and, for convenience, has been termed hyperintense acute reperfusion marker (HARM). HARM was found in 47 of 144 (33%) ischemic stroke patients. Reperfusion was found to be the strongest independent predictor of early BBB disruption (P=0.018) in multivariate analysis. HARM was associated with HT and worse clinical outcome (after adjustment for initial severity). It was also associated with more severe strokes at onset and greater age. Because the timing of the disruption was early enough (median estimate 3.8 hours from onset) to make it relevant to acute thrombolytic therapy, early BBB disruption as defined by HARM may be a promising target for adjunctive therapy to reduce the complications associated with thrombolytic therapy, broaden the therapeutic window, and improve clinical outcome.
缺血再灌注导致的血脑屏障(BBB)完整性丧失被认为是出血性转化(HT)的先兆,且会导致比预期的再灌注有益效果更差的临床结果。我们使用一种新型磁共振成像标记物来表征急性局灶性脑缺血早期的血脑屏障破坏情况,并测试其与再灌注、HT及不良预后(改良Rankin量表评分>2)的相关性。血脑屏障破坏表现为液体衰减反转恢复(FLAIR)图像上脑脊液间隙的钆延迟强化,为方便起见,将其称为高强度急性再灌注标记物(HARM)。在144例缺血性卒中患者中,有47例(33%)发现了HARM。在多变量分析中,再灌注被发现是早期血脑屏障破坏的最强独立预测因素(P=0.018)。HARM与HT及更差的临床结果相关(在调整初始严重程度后)。它还与发病时更严重的卒中及更高的年龄相关。由于破坏发生的时间足够早(中位估计发病后3.8小时),与急性溶栓治疗相关,因此由HARM定义的早期血脑屏障破坏可能是辅助治疗的一个有前景的靶点,以减少与溶栓治疗相关的并发症,拓宽治疗窗口,并改善临床结果。